SeekingAlpha · Aug 3, 2026
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications
Alto Neuroscience's diversified pipeline and biomarker-driven strategies support continued optimism. Learn why ANRO stock is a Buy.
AN
NYSE · ANRO
Alto Neuroscience, Inc.
Healthcare · Biotechnology
$32.30
Down-$0.90 (-2.79%)
Updated Aug 14, 2026, 1:40 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 611.7M
- P/E ratio
- -8.57
- Dividend yield
- 0.00%
- 52-week range
- $17.90 – $29.70
- Volume
- 989.98K
- Avg. volume
- 287.35K
Price performance
ANRO price history
1M range · 21 trading sessions · Daily adjusted prices
ANRO closed at $32.30 after 21 trading sessions, up 18.19% for the selected period.
- Last close
- $32.30
- Period change
- +18.19%
- Period low
- $25.90
- Period high
- $32.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $30.00 | $33.67 | $29.59 | $32.30 | 989.98K |
| Aug 12, 2026 | $28.24 | $29.70 | $28.24 | $29.18 | 278.06K |
| Aug 11, 2026 | $28.49 | $29.06 | $27.43 | $28.78 | 228.52K |
| Aug 10, 2026 | $28.64 | $29.15 | $27.40 | $28.29 | 417.96K |
| Aug 7, 2026 | $29.00 | $29.2481 | $27.71 | $28.67 | 336.43K |
| Aug 6, 2026 | $27.99 | $29.49 | $27.6691 | $28.47 | 421.15K |
| Aug 5, 2026 | $28.51 | $28.54 | $27.00 | $28.03 | 248.89K |
| Aug 4, 2026 | $27.79 | $28.50 | $27.00 | $28.23 | 555.44K |
| Aug 3, 2026 | $27.00 | $27.625 | $25.80 | $27.27 | 409.07K |
| Jul 31, 2026 | $28.50 | $28.80 | $26.89 | $27.07 | 323.67K |
| Jul 30, 2026 | $27.09 | $28.75 | $26.51 | $28.63 | 349.66K |
| Jul 29, 2026 | $27.60 | $28.07 | $26.60 | $26.72 | 300.21K |
| Jul 28, 2026 | $28.00 | $28.00 | $26.51 | $27.42 | 410.77K |
| Jul 27, 2026 | $26.63 | $28.315 | $26.47 | $27.87 | 499.76K |
| Jul 24, 2026 | $27.28 | $27.89 | $25.72 | $26.78 | 295.57K |
| Jul 23, 2026 | $26.67 | $27.21 | $26.46 | $26.85 | 257.88K |
| Jul 22, 2026 | $26.54 | $27.59 | $26.0001 | $27.23 | 395.02K |
| Jul 21, 2026 | $26.05 | $27.46 | $25.96 | $27.07 | 437.46K |
| Jul 20, 2026 | $27.51 | $28.63 | $25.66 | $25.90 | 617.91K |
| Jul 17, 2026 | $26.63 | $28.82 | $26.44 | $27.54 | 777.37K |
| Jul 16, 2026 | $27.575 | $28.56 | $26.70 | $27.33 | 545.91K |
Latest ANRO news
The latest Smart Investors Daily articles mentioning ANRO.
Stock researchCompany · Overview
ANRO research
Overview
Company profile and research snapshot.
Company profile
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $16.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Neutral | — |
| Aug 13, 2026 | BTIG | Buy | — |
| May 18, 2026 | Baird | Outperform | — |
| May 14, 2026 | Wedbush | Neutral | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 13, 2026
Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/Share
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment
Benzinga · Jul 13, 2026
Alto Neuroscience Intends To Accelerate And Expand Clinical Development Of ALTO-207, Including An Additional Planned Phase 3 Trial As Monotherapy For Treatment-Resistant Depression
On July 13, 2026, Alto Neuroscience, Inc. (the "Company") announced that, based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and restricted
Yahoo · Jun 15, 2026
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
MOUNTAIN VIEW, Calif., June 15, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
